menu
    • menu

    Find Flurazepam manufacturers, exporters & distributors on PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    4

    API Suppliers

    API Suppliers

    3

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    1

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    2

    NDC API

    NDC API

    0

    VMF

    NDC API

    1

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 773

    MARKET PLACE

    1

    API

    1

    FDF

    1INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    49

    FDF Dossiers

    FDF Dossiers

    26

    FDA Orange Book

    FDA (Orange Book)

    16

    Europe

    Europe

    3

    Canada

    Canada

    0

    Australia

    Australia

    2

    South Africa

    South Africa

    2

    Listed Dossiers

    Listed Dossiers

    0 DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    1

    EDQM

    2

    USP

    0

    JP

    3

    Others

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    0

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    93,533

    Annual Reports

    NA

    Finished Drug Prices

    Listed Dossiers

    135 RELATED EXCIPIENT COMPANIES

    217EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 17617-23-1, Insumin, Dalmane, Flurazepamum, Flurazepam hcl, 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-3h-1,4-benzodiazepin-2-one
    Molecular Formula
    C21H23ClFN3O
    Molecular Weight
    387.9  g/mol
    InChI Key
    SAADBVWGJQAEFS-UHFFFAOYSA-N
    FDA UNII
    IHP475989U
    Flurazepam
    A benzodiazepine derivative used mainly as a hypnotic.
    Flurazepam is a Benzodiazepine.
    1 2D Structure

    Flurazepam

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one
    2.1.2 InChI
    InChI=1S/C21H23ClFN3O/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23/h5-10,13H,3-4,11-12,14H2,1-2H3
    2.1.3 InChI Key
    SAADBVWGJQAEFS-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CCN(CC)CCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F
    2.2 Other Identifiers
    2.2.1 UNII
    IHP475989U
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Apo Flurazepam

    2. Apo-flurazepam

    3. Dalmadorm

    4. Dalmane

    5. Dihydrochloride, Flurazepam

    6. Dormodor

    7. Flurazepam Dihydrochloride

    8. Flurazepam Hydrochloride

    9. Flurazepam Mono Perchlorate

    10. Flurazepam Mono-perchlorate

    11. Flurazepam Monohydrochloride

    12. Hydrochloride, Flurazepam

    13. Mono-perchlorate, Flurazepam

    14. Monohydrochloride, Flurazepam

    15. Staurodorm

    2.3.2 Depositor-Supplied Synonyms

    1. 17617-23-1

    2. Insumin

    3. Dalmane

    4. Flurazepamum

    5. Flurazepam Hcl

    6. 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-3h-1,4-benzodiazepin-2-one

    7. 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-2h-1,4-benzodiazepin-2-one

    8. 7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1h-1,4-benzodiazepin-2(3h)-one

    9. Stauroderm

    10. Noctosom

    11. Ihp475989u

    12. Dalmane-r

    13. 2h-1,4-benzodiazepin-2-one, 7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1,3-dihydro-

    14. 2h-1,4-benzodiazepin-2-one, 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-

    15. 7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1,3-dihydro-2h-1,4-benzodiazepin-2-one

    16. Dea No. 2767

    17. Ncgc00164573-01

    18. Felmane

    19. Dsstox_cid_3071

    20. Dsstox_rid_76863

    21. Dsstox_gsid_23071

    22. 2h-1,4-benzodiazepin-2-one, 1,3-dihydro-7-chloro-1-(2-(diethylamino)ethyl)-5-(o-fluorophenyl)-

    23. 2h-1,4-benzodiazepin-2-one, 7-chloro-1-[2-(diethylamino)ethyl]-5-(o-fluorophenyl)-1,3-dihydro-

    24. Flurazepamum [inn-latin]

    25. Flurazepam [inn:ban:jan]

    26. 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-2,3-dihydro-1h-1,4-benzodiazepin-2-one

    27. Insumin (tn)

    28. Cas-17617-23-1

    29. Ro-5-6901/3

    30. Hsdb 3085

    31. Einecs 241-591-7

    32. Brn 0767925

    33. Unii-ihp475989u

    34. 7-chloro-1-(2-(diethylamino)ethyl)-5-(o-fluorophenyl)-1,3-dihydro-2h-1,4-benzodiazepin-2-one

    35. 7-chloro-1-[2-(diethylamino)ethyl]-5-(o-fluorophenyl)-1,3-dihydro-2h-1,4-benzodiazepin-2-one

    36. Flurazepam [mi]

    37. Flurazepam (jan/inn)

    38. Flurazepam [inn]

    39. Flurazepam [jan]

    40. Flurazepam [hsdb]

    41. Flurazepam [vandf]

    42. Chembl968

    43. Flurazepam [mart.]

    44. Flurazepam [who-dd]

    45. Schembl29793

    46. 5-24-04-00322 (beilstein Handbook Reference)

    47. Chebi:5128

    48. Gtpl7188

    49. Dtxsid1023071

    50. 17617-23-1(free Base)

    51. Zinc537752

    52. Flurazepam 0.1 Mg/ml In Methanol

    53. Flurazepam 1.0 Mg/ml In Methanol

    54. Tox21_112201

    55. Ro-56901

    56. Akos015889971

    57. Tox21_112201_1

    58. Db00690

    59. Ncgc00164573-02

    60. Ro 56901/3

    61. Db-044253

    62. D00329

    63. 617f231

    64. A812156

    65. Q418998

    66. 7-chloranyl-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-3h-1,4-benzodiazepin-2-one

    67. Flurazepam Solution, 1.0 Mg/ml In Methanol, Ampule Of 1 Ml, Certified Reference Material

    68. Flurazepam-d4 Solution, 100 Mug/ml In Methanol, Certified Reference Material

    69. (e)-7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1h-benzo[e][1,4]diazepin-2(3h)-one

    70. 2h-1,4-benzodiazepin-2-one, 7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1,3-dihydro

    71. 7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1h-benzo[e][1,4]diazepin-2(3h)-one

    72. 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-2h-1,4-benzodiazepin-2-one #

    73. Fl7

    2.4 Create Date
    2005-03-25
    3 Chemical and Physical Properties
    Molecular Weight 387.9 g/mol
    Molecular Formula C21H23ClFN3O
    XLogP33
    Hydrogen Bond Donor Count0
    Hydrogen Bond Acceptor Count4
    Rotatable Bond Count6
    Exact Mass387.1513682 g/mol
    Monoisotopic Mass387.1513682 g/mol
    Topological Polar Surface Area35.9 Ų
    Heavy Atom Count27
    Formal Charge0
    Complexity540
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameFlurazepam hydrochloride
    Drug LabelFlurazepam hydrochloride is chemically 7-chloro-1-[2-(diethylamino)ethyl]-5-(o-fluoro-phenyl)-1,3dihydro-2H-1,4-benzodiazepin-2-one dihydrochloride. It is a pale yellow, crystalline compound, freely soluble in alcohol and very soluble in water. It ha...
    Active IngredientFlurazepam hydrochloride
    Dosage FormCapsule
    RouteOral
    Strength30mg; 15mg
    Market StatusPrescription
    CompanyMylan Pharms

    2 of 2  
    Drug NameFlurazepam hydrochloride
    Drug LabelFlurazepam hydrochloride is chemically 7-chloro-1-[2-(diethylamino)ethyl]-5-(o-fluoro-phenyl)-1,3dihydro-2H-1,4-benzodiazepin-2-one dihydrochloride. It is a pale yellow, crystalline compound, freely soluble in alcohol and very soluble in water. It ha...
    Active IngredientFlurazepam hydrochloride
    Dosage FormCapsule
    RouteOral
    Strength30mg; 15mg
    Market StatusPrescription
    CompanyMylan Pharms

    4.2 Therapeutic Uses

    Anti-Anxiety Agents, Benzodiazepine; GABA Modulators; Sedatives, Nonbarbiturate

    National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)

    A BENZODIAZEPINE WIDELY USED IN ALL TYPES OF INSOMNIA SUCH AS DIFFICULTY IN FALLING ASLEEP, FREQUENT NOCTURNAL AWAKENINGS, &/OR EARLY MORNING AWAKENING. IT IS ALSO USEFUL IN ACUTE & CHRONIC MEDICAL SITUATIONS IN WHICH RESTFUL SLEEP IS DESIRABLE. /FLURAZEPAM DIHYDROCHLORIDE/

    Osol, A. (ed.). Remington's Pharmaceutical Sciences. 16th ed. Easton, Pennsylvania: Mack Publishing Co., 1980., p. 1007

    FOR PATIENTS RECEIVING ORAL ANTICOAGULANTS, FLURAZEPAM IS SUITABLE & SAFE HYPNOTIC AGENT

    Evaluations of Drug Interactions. 2nd ed. and supplements. Washington, DC: American Pharmaceutical Assn., 1976, 1978., p. 277

    HYPNOTIC EFFECTS BEGIN IN AN AVERAGE OF 17 MINUTES AFTER ORAL ADMIN & LAST 7 TO 8 HR. IN A SMALL CONTROLLED SLEEP STUDY, FLURAZEPAM WAS REPORTED TO MAINTAIN ITS EFFECTIVENESS FOR UP TO 4 WK. /FLURAZEPAM DIHYDROCHLORIDE/

    American Medical Association. AMA Drug Evaluations Annual 1991. Chicago, IL: American Medical Association, 1991., p. 218

    Sedative /Flurazepam dihydrochloride/

    Budavari, S. (ed.). The Merck Index - Encyclopedia of Chemicals, Drugs and Biologicals. Rahway, NJ: Merck and Co., Inc., 1989., p. 657

    4.3 Drug Warning

    THE EFFICACY OF DRUG BEYOND 22 CONSECUTIVE NIGHTS OF USE IS NOT KNOWN. IN ONE STUDY, PATIENTS RATED FLURAZEPAM MORE HIGHLY THAN SECOBARBITAL ... . FLURAZEPAM SHOULD BE USED CAUTIOUSLY WHEN HEPATIC OR RENAL FUNCTION IS IMPAIRED. /FLURAZEPAM DIHYDROCHLORIDE/

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 125

    CAUTION: ABUSE MAY LEAD TO HABITUATION OR ADDICTION. /FLURAZEPAM DIHYDROCHLORIDE/

    Budavari, S. (ed.). The Merck Index - Encyclopedia of Chemicals, Drugs and Biologicals. Rahway, NJ: Merck and Co., Inc., 1989., p. 601

    PATIENT STATUS EPILEPTICUS IN PATIENTS WITH LENNOX-GASTAUT SYNDROME (PETIT MAL VARIANT). /BENZODIAZEPINES/

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 217

    PATIENTS ON THESE DRUGS SHOULD BE WARNED ... NOT TO OPERATE A MOTOR VEHICLE OR HAZARDOUS MACHINERY ... /BENZODIAZEPINES/

    Osol, A. (ed.). Remington's Pharmaceutical Sciences. 16th ed. Easton, Pennsylvania: Mack Publishing Co., 1980., p. 1005

    For more Drug Warnings (Complete) data for FLURAZEPAM (13 total), please visit the HSDB record page.

    4.4 Drug Indication

    For short-term and intermittent use in patients with recurring insomnia and poor sleeping habits

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Flurazepam, a benzodiazepine derivative, is a hypnotic agent which does not appear to decrease dream time as measured by rapid eye movements (REM). Furthermore, it decreases sleep latency and number of awakenings for a consequent increase in total sleep time.

    5.2 MeSH Pharmacological Classification

    Hypnotics and Sedatives

    Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)

    Anti-Anxiety Agents

    Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)

    GABA Modulators

    Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    FLURAZEPAM
    5.3.2 FDA UNII
    IHP475989U
    5.3.3 Pharmacological Classes
    Chemical Structure [CS] - Benzodiazepines
    5.4 ATC Code

    N - Nervous system

    N05 - Psycholeptics

    N05C - Hypnotics and sedatives

    N05CD - Benzodiazepine derivatives

    N05CD01 - Flurazepam

    5.5 Absorption, Distribution and Excretion

    Absorption

    Flurazepam hydrochloride is rapidly (30 minutes) absorbed from the gastrointestinal tract

    Route of Elimination

    Flurazepam is rapidly metabolized and is excreted primarily in the urine. Less than 1% of the dose is excreted in the urine as N1-desalkyl-flurazepam.

    HYPNOTIC, FLURAZEPAM HYDROCHLORIDE, HAS BEEN SHOWN TO BE RAPIDLY & COMPLETELY ABSORBED IN DOG & MAN. ELIMINATION IS ALSO RAPID & DUE SOLELY TO BIOTRANSFORMATION. /FLURAZEPAM HYDROCHLORIDE/

    The Chemical Society. Foreign Compound Metabolism in Mammals. Volume 2: A Review of the Literature Published Between 1970 and 1971. London: The Chemical Society, 1972., p. 444

    ORAL ... ((14)CARBON) FLURAZEPAM ... IN DOG & MAN ... ELIMINATED MAINLY IN 3 DAYS. DOG EXCRETED 36 & 49% OF (14)CARBON IN URINE & FECES (PROBABLY VIA BILE) FOLLOWING ORAL DOSE & 27 & 54% FOLLOWING IV DOSE. AFTER ORAL DOSE, HUMANS EXCRETED ... IN FECES (9%) & ... IN URINE (81%). PLASMA (14)CARBON ... PEAKED IN 1 HR FOLLOWING ORAL DOSE IN BOTH SPECIES.

    The Chemical Society. Foreign Compound Metabolism in Mammals. Volume 2: A Review of the Literature Published Between 1970 and 1971. London: The Chemical Society, 1972., p. 87

    ALL BENZODIAZEPINES BIND TO HUMAN PLASMA ALBUMIN. THE EXTENT OF BINDING VARIES FROM PROBABLY ONLY A FEW PERCENT WITH FLURAZEPAM TO NEARLY 99% WITH DIAZEPAM.

    Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 347

    THE BIOAVAILABILITY OF FLURAZEPAM VARIES BETWEEN 30 & 60%. AFTER A SINGLE ORAL DOSE OF 30 MG, THE PLASMA CONCN RISES TO A PEAK OF 1 TO 2 NG/ML AT 1 HR & FALLS RAPIDLY WITH HALF-LIFE OF ABOUT 3 HR... AFTER A 30 MG DOSE OF FLURAZEPAM, THE PEAK CONCN (AT 1 TO 3 HR) OF THE DESALKYL METABOLITE IS 0.5 TO 1.8 NG/ML & THAT OF THE DESAMINO COMPOUNDS IS 6 TO 8 NG/ML. THE ELIMINATION HALF-LIFE OF THE DESAMINO COMPOUND IS 10 TO 20 HR & THAT OF THE DESALKYL METABOLITE IS 1 DAY OR LONGER. THEREFORE, WITH DAILY ADMIN, THESE METABOLITES ACCUMULATE TO RATHER HIGH CONCN OVER A PERIOD OF SEVERAL DAYS TO A FEW WK. SINCE PHARMACOLOGICAL ACTIVITY IS ATTRIBUTABLE TO THESE METABOLITES, A FEW DAYS OF DAILY ADMIN ARE REQUIRED FOR THE ONSET OF THE FULL EFFECT OF FLURAZEPAM, & RESIDUAL EFFECTS ("HANGOVER") ARE COMMON. LESS THAN 0.2% OF FLURAZEPAM IS EXCRETED UNCHANGED; 30 TO 55% OF THE DRUG IS CONVERTED TO THE DESAMINO METABOLITE.

    Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 348

    For more Absorption, Distribution and Excretion (Complete) data for FLURAZEPAM (8 total), please visit the HSDB record page.

    5.6 Metabolism/Metabolites

    Flurazepam is rapidly metabolized and is excreted primarily in the urine. Both hydroxyethyl flurazepam (the major metabolite) and N-desalkyl flurazepam are active. The N-desalkyl metabolite is slowly excreted in the urine as the conjugated form

    IT IS METABOLIZED IN LIVER. THE DIETHYLAMINE GROUP IS DESETHYLATED, THEN DEAMINATED, EVENTUALLY TO YIELD ALCOHOL, THE MAJOR METABOLITE IN MAN. ALCOHOL IS CONJUGATED TO FORM THE GLUCURONIDE. THE PHENYL RING IS ALSO HYDROXYLATED AT THE ORTHO POSITION, THEN CONJUGATED. THE HETEROCYCLIC RING IS ALSO HYDROXYLATED. /FLURAZEPAM DIHYDROCHLORIDE/

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 125

    YIELDS 7-CHLORO-1-(2-ETHYLAMINOETHYL)-5-(2-FLUOROPHENYL)-1,3-DIHYDRO-2H- 1,4-BENZODIAZEPIN-2-ONE IN MAN & IN DOG & YIELDS 7-CHLORO-5-(2-FLUOROPHENYL)-1,3-DIHYDRO-2H-1,4-BENZODIAZEPIN-2-ONE IN MAN. /FROM TABLE/

    Goodwin, B.L. Handbook of Intermediary Metabolism of Aromatic Compounds. New York: Wiley, 1976., p. C-23

    YIELDS 7-CHLORO-1-(N-ETHYL-N-(2-HYDROXYETHYL)AMINOETHYL)-5-(2-FLUOROPHENYL)- 1,3-DIHYDRO-2H-1,4-BENZODIAZEPIN-2-ONE IN MAN & YIELDS 7-CHLORO-5-(2-FLUOROPHENYL)-1,3-DIHYDRO-3-HYDROXY-2H-1,4-BENZODIAZEPIN-2-ONE IN DOGS. /FROM TABLE/

    Goodwin, B.L. Handbook of Intermediary Metabolism of Aromatic Compounds. New York: Wiley, 1976., p. C-23

    AFTER CHRONIC ORAL DOSES OF FLURAZEPAM TO HUMAN SUBJECTS, UNCHANGED DRUG COULD NOT BE DETECTED IN BLOOD, & MAJOR CMPD PRESENT WAS N-DEALKYL-FLURAZEPAM. BIOLOGICAL HALF-LIFE OF THIS METABOLITE RANGED FROM 47-100 HR.

    The Chemical Society. Foreign Compound Metabolism in Mammals Volume 3. London: The Chemical Society, 1975., p. 120

    For more Metabolism/Metabolites (Complete) data for FLURAZEPAM (10 total), please visit the HSDB record page.

    5.7 Biological Half-Life

    The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours

    Half-life of flurazepam in plasma is 2 to 3 hr, but that of a major active metabolite (N-desalkylflurazepam) is 50 hr or more.

    Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 353

    Elimination half-lives of metabolites: Desalkylflurazepam (47-100 hr) and N-1-Hydroxyethylflurazepam (2-4 hr) /From table/

    McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 92. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1992 (Plus Supplements 1992)., p. 1331

    MEAN HALF-LIFE (IN HOURS) ARE: 74 FOR YOUNG MALES & 160 FOR ELDERLY MALES; 90 FOR YOUNG FEMALES & 120 FOR ELDERLY FEMALES. /FLURAZEPAM HYDROCHLORIDE/

    American Medical Association. AMA Drug Evaluations Annual 1991. Chicago, IL: American Medical Association, 1991., p. 218

    5.8 Mechanism of Action

    Flurazepam binds to an allosteric site on GABA-A receptors. Binding potentiates the action of GABA on GABA-A receptors by opening the chloride channel within the receptor, causing chloride influx and hyperpolarization.

    EFFECTS OF FLURAZEPAM ON EEG DIFFER FROM THOSE OF BARBITURATES IN THAT FAST ACTIVITY SEEMS TO BE INCREASED ONLY IN FRONTAL LOBE & DOES NOT SPREAD TO OCCIPITAL LOBE. IN DOSES UP TO 30 MG IT NEITHER AFFECTS REM SLEEP NOR CAUSES A REBOUND AFTER WITHDRAWAL, BUT DOSES OF 60 MG SUPPRESS REM SLEEP WITHOUT REBOUND. FLURAZEPAM DECREASES SLEEP LATENCY, TIME IN STAGE 4, & WAKE TIME, & INCREASES TOTAL SLEEP TIME FOR AS LONG AS 22 NIGHTS OF USE. /FLURAZEPAM DIHYDROCHLORIDE/

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 125

    MOST BENZODIAZEPINES DECREASE SLEEP LATENCY, ESPECIALLY WHEN FIRST USED, & DIMINISH THE NUMBER OF AWAKENINGS & TIME SPENT IN STAGE 0 (A STAGE OF WAKEFULNESS). THEY HAVE BEEN SHOWN TO INCREASE THE AWAKENING THRESHOLD. TIME IN STAGE 1 (DESCENDING DROWSINESS) IS USUALLY DECREASED BY FLURAZEPAM ... . TIME SPENT IN STAGE 2 (WHICH IS THE MAJOR FRACTION OF NON-RAPID EYE MOVEMENT (REM) SLEEP) IS INCREASED BY ALL BENZODIAZEPINES. BENZODIAZEPINES PROMINENTLY DECREASE THE TIME SPENT IN SLOW-WAVE SLEEP (SWS; STAGES 3 & 4); USUALLY BOTH STAGES 3 & 4 ARE SHORTENED ... . ALL BENZODIAZEPINES INCREASE REM LATENCY (TIME FROM ONSET OF SPINDLE SLEEP TO THE FIRST REM BURST), EXCEPT THAT FLURAZEPAM HAS BEEN REPORTED TO SHORTEN LATENCY IN SOME INSOMNIAC NEUROTIC OR PSYCHOTIC INDIVIDUALS. ... REM SLEEP MAY NOT BE SHORTENED WHEN LOWER DOSES OF FLURAZEPAM ... /WAS/ USED, EVEN THOUGH SUBSTANTIAL SHORTENING OF SLOW-WAVE SLEEP & PROLONGATION OF STAGE 2 SLEEP MAY OCCUR. ... DESPITE THE SHORTENING OF STAGE-4 & REM SLEEP, THE NET EFFECT OF ADMIN OF BENZODIAZEPINES IS AN INCREASE IN TOTAL SLEEP TIME.

    Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 342

    WITH FLURAZEPAM ... THE REBOUND IN REM SLEEP APPEARS TO BE SLIGHT OR NEGLIGIBLE. DURING THE PERIOD OF SUCH REBOUND THE NUMBER OF DREAMS PER NIGHT IS ABOUT THE SAME AS BEFORE THE DRUG WAS TAKEN, BUT THEIR BIZARRE CHARACTER MAY INCREASE. THERE IS ALSO USUALLY A REBOUND IN SLOW-WAVE SLEEP WHICH MAY EXCEED THE REBOUND IN REM SLEEP. WITHDRAWAL OF FLURAZEPAM CAUSES ONLY A SLIGHT REBOUND. ... TOTAL WAKE TIME IS NOT CHANGED AFTER WITHDRAWAL OF FLURAZEPAM.

    Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 344

    THE BENZODIAZEPINES SELECTIVELY ACT ON POLYSYNAPTIC & NOT MONOSYNAPTIC NEURONAL PATHWAYS THROUGHOUT THE CNS. THE ACTION IS MAINLY THAT OF PRESYNAPTIC INHIBITION, ALTHOUGH AT SOME SITES, SUCH AS IN CUNEATE NUCLEUS, THERE MAY BE POSTSYNAPTIC INHIBITION; WHETHER INHIBITION IS PRESYNAPTIC OR POSTSYNAPTIC, IT SIMULATES THAT OF GAMMA-AMINOBUTYRIC ACID. POLYSYNAPTIC RESPONSES MAY BE DIMINISHED OR AUGMENTED, ACCORDING TO WHETHER SYNAPTIC INHIBITION SUBSERVES AN INHIBITORY OR FACILITATORY FUNCTION IN THE INTEGRATED RESPONSE. /BENZODIAZEPINES/

    Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 344

    For more Mechanism of Action (Complete) data for FLURAZEPAM (10 total), please visit the HSDB record page.

    API SUPPLIERS

    read-more
    read-more
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1659119400,"product":"FLURAZEPAM MONO HCL BP","address":"CENTAUR HOUSE, SHANTI NAGAR,,VAKOL A, SANTACRUZ - EAST","city":"MUMBAI,MAHARASHTRA","supplier":"CENTAUR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"M\/S.","customerCountry":"BANGLADESH","quantity":"95.00","actualQuantity":"95","unit":"KGS","unitRateFc":"400","totalValueFC":"37828.6","currency":"USD","unitRateINR":31663.157894736843,"date":"30-Jul-2022","totalValueINR":"3008000","totalValueInUsd":"37828.6","indian_port":"BOMBAY AIR","hs_no":"29339100","bill_no":"3186022","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"CENTAUR HOUSE, SHANTI NAGAR,,VAKOL A, SANTACRUZ - EAST, MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1690914600,"product":"PHARMACEUTICAL RAW MATERIAL FLURAZEPAM D","address":"NA","city":"BANGALORE","supplier":"LAKE CHEMICALS P LIMITED","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"Z TO ORDER AND NA","customerCountry":"TAIWAN","quantity":"110.00","actualQuantity":"110","unit":"KGS","unitRateFc":"784","totalValueFC":"84794.7","currency":"USD","unitRateINR":63855.26337272727,"date":"02-Aug-2023","totalValueINR":"7024078.971","totalValueInUsd":"84794.7","indian_port":"BANGALORE AIR","hs_no":"29339100","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"NA, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1696012200,"product":"PHARMACEUTICAL RAW MATERIAL-FLURAZEPAM MONOHYDROCHLORIDE BP BATCH NO.843023001EMFG DT.SEPTEMBER-2023 EXP DT.AUGUST-2028","address":"5TH FLOOR,LAXMINARAYAN COMPLEX","city":"BANGALORE, KARNATAKA","supplier":"LAKE CHEMICALS PRIVATE ","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"TO THE ORDER OF,","customerCountry":"BANGLADESH","quantity":"70.00","actualQuantity":"70","unit":"KGS","unitRateFc":"750","totalValueFC":"51753.9","currency":"USD","unitRateINR":61371.428571428572,"date":"30-Sep-2023","totalValueINR":"4296000","totalValueInUsd":"51753.9","indian_port":"Bangalore Air","hs_no":"29339100","bill_no":"4303515","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Bangalore Air","supplierAddress":"5TH FLOOR,LAXMINARAYAN COMPLEX, BANGALORE, KARNATAKA","customerAddress":""}]
    30-Jul-2022
    30-Sep-2023
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Granulation

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Topical

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    USP

    read-more
    read-more

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search